1. Home
  2. MIRM vs FITBO Comparison

MIRM vs FITBO Comparison

Compare MIRM & FITBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • FITBO
  • Stock Information
  • Founded
  • MIRM 2018
  • FITBO N/A
  • Country
  • MIRM United States
  • FITBO United States
  • Employees
  • MIRM N/A
  • FITBO 18607
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • FITBO Major Banks
  • Sector
  • MIRM Health Care
  • FITBO Finance
  • Exchange
  • MIRM Nasdaq
  • FITBO Nasdaq
  • Market Cap
  • MIRM 2.5B
  • FITBO N/A
  • IPO Year
  • MIRM 2019
  • FITBO N/A
  • Fundamental
  • Price
  • MIRM $52.66
  • FITBO $20.19
  • Analyst Decision
  • MIRM Strong Buy
  • FITBO
  • Analyst Count
  • MIRM 9
  • FITBO 0
  • Target Price
  • MIRM $66.22
  • FITBO N/A
  • AVG Volume (30 Days)
  • MIRM 465.4K
  • FITBO N/A
  • Earning Date
  • MIRM 08-06-2025
  • FITBO N/A
  • Dividend Yield
  • MIRM N/A
  • FITBO N/A
  • EPS Growth
  • MIRM N/A
  • FITBO N/A
  • EPS
  • MIRM N/A
  • FITBO N/A
  • Revenue
  • MIRM $379,251,000.00
  • FITBO N/A
  • Revenue This Year
  • MIRM $35.83
  • FITBO N/A
  • Revenue Next Year
  • MIRM $16.83
  • FITBO N/A
  • P/E Ratio
  • MIRM N/A
  • FITBO N/A
  • Revenue Growth
  • MIRM 69.31
  • FITBO N/A
  • 52 Week Low
  • MIRM $36.17
  • FITBO N/A
  • 52 Week High
  • MIRM $54.23
  • FITBO N/A
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 64.66
  • FITBO 50.17
  • Support Level
  • MIRM $49.22
  • FITBO $19.81
  • Resistance Level
  • MIRM $53.86
  • FITBO $20.43
  • Average True Range (ATR)
  • MIRM 1.57
  • FITBO 0.22
  • MACD
  • MIRM 0.08
  • FITBO 0.09
  • Stochastic Oscillator
  • MIRM 79.63
  • FITBO 69.23

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About FITBO Fifth Third Bancorp Depositary Shares each representing a 1/1000th ownership interest in a share of Non-Cumulative Perpetual Preferred Stock Series K

Fifth Third Bancorp is a diversified financial-services company headquartered in Cincinnati. The company has over $200 billion in assets and operates numerous full-service banking branches and ATMs throughout Ohio, Kentucky, Indiana, Michigan, Illinois, Florida, Tennessee, West Virginia, Georgia, and North Carolina.

Share on Social Networks: